Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Moderate Buy” by Analysts

Precigen, Inc. (NASDAQ:PGEN) has earned an average recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $7.00.

Several equities research analysts have recently weighed in on PGEN shares. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Precigen in a research report on Thursday, January 23rd.

Precigen Stock Up 3.1 %

NASDAQ PGEN opened at $2.02 on Friday. The company has a market capitalization of $591.60 million, a price-to-earnings ratio of -3.67 and a beta of 1.66. Precigen has a twelve month low of $0.65 and a twelve month high of $2.17. The stock has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $1.05.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets acquired a new stake in Precigen during the fourth quarter worth approximately $27,000. Traphagen Investment Advisors LLC bought a new position in shares of Precigen during the 3rd quarter worth approximately $29,000. Stifel Financial Corp grew its position in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after buying an additional 15,680 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 5,915 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new position in shares of Precigen during the 4th quarter valued at $35,000. 33.51% of the stock is owned by institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.